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Background: Tick-borne diseases comprise a group of maladies that are of substantial medical and veterinary
significance. A range of tick-borne pathogens, including diverse species of bacteria and protozoa, can infect both
dogs and humans. Hence, the control of tick infestations is pivotal to decrease or prevent tick-borne pathogen
transmission. Therefore, different commercial products with insecticidal, repellent or both properties have been
developed for use on dogs. Recently, a collar containing a combination of imidacloprid 10% and flumethrin 4.5%
has proven effective to prevent tick and flea infestations in dogs under field conditions and the infection by some
vector-borne pathogens they transmit under laboratory-controlled conditions.
Methods: From March 2011 to April 2012, a field study was conducted in a private shelter in southern Italy to
assess the efficacy of the imidacloprid/flumethrin collar against tick and flea infestations and to determine if this
strategy would decrease tick-borne pathogen transmission in young dogs. A total of 122 animals were enrolled in
the study and randomly assigned to group A (n = 64; collared) or group B (n = 58; untreated controls). Dogs were
examined monthly for ticks and fleas and systematically tested for selected tick-borne pathogens.
Results: Compared to controls, the collar provided overall efficacies of 99.7% and 100% against tick and flea
infestation, respectively. The overall efficacy for the prevention of tick-borne pathogens (i.e., Anaplasma platys and
Babesia vogeli) was 91.6%.
Conclusions: This study demonstrates that the imidacloprid/flumethrin collar is efficacious against flea and tick
infestation as well as tick-borne pathogen transmission to dogs under field conditions.
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Tick-borne diseases (TBDs) comprise a group of ill-
nesses caused by numerous pathogens (e.g., viruses, bac-
teria, protozoa, and helminths) that may be transmitted
by a number of tick species [1]. These diseases may
range from subclinical to life-threatening conditions,
with the severity of clinical signs depending on the
microorganism(s) involved and the host immune* Correspondence: domenico.otranto@uniba.it
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distribution, and reproduction in any mediumresponse against the infection [2,3]. Importantly, some
pathogens transmitted by certain tick species belonging
to the Rhipicephalus sanguineus group are primarily
found in association with dogs, but may potentially in-
fect humans, as is the case of Ehrlichia canis, Rickettsia
conorii, Rickettsia massiliae, and Rickettsia rickettsii [1].
These observations highlight the importance of control-
ling tick infestations in dogs, so as to reduce the risk of
tick-borne infections in pets and family members.
The Mediterranean region provides a suitable environ-
ment for the development of a range of tick species,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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some TBD-causing pathogens (e.g., Anaplasma platys,
Babesia vogeli, E. canis and Hepatozoon canis) are wide-
spread and highly prevalent in some Mediterranean
countries [2,4-6]. In highly endemic areas, the typical
clinical presentation associated with individual TBDs in
dogs may potentially be masked by simultaneous infec-
tions by multiple pathogens [3,7].
Clearly, the risk of contracting TBDs is directly associ-
ated with the exposure to tick vectors. Therefore, the
use of insecticides and repellents is currently considered
the best option to prevent infections by tick-borne path-
ogens in dogs [8]. For instance, a spot-on formulation
containing 10% imidacloprid and 50% permethrin
(AdvantixW, Bayer HealthCare AG, Germany) has
proven effective in protecting dogs against tick infesta-
tions under field conditions, as well as in preventing the
transmission of selected tick-borne pathogens [9,10]. Re-
cently, a collar containing 10% imidacloprid and 4.5%
flumethrin (SerestoW, Bayer Animal Health, Germany)
was developed for use on dogs and cats. This product
contains both repellent and insecticidal properties and
has proven effective against fleas, ticks, mites and lice
[11-15]. The imidacloprid/flumethrin collar was highly
efficacious in curing animals living in communities
highly infested with ticks and fleas and to prevent
reinfestations for up to 8 months in a refuge with a his-
tory of unsuccessful environmental tick control [16].
Furthermore, recent laboratory studies have demon-
strated the efficacy of this collar for the prevention of
vector-borne pathogen transmission in both dogs and
cats [17-20]. Specifically in dogs, this collar was effective
in preventing the transmission of Babesia canis and E.
canis by ticks [18,19] as well as of Dipylidium caninum
by the cat flea Ctenocephalides felis [17], under
laboratory-controlled conditions. More recently, this col-
lar was proven highly efficacious against L. infantum in-
fection under field conditions [21]. Herein, we assessed
the efficacy of this new device against tick and flea in-
festation as well as its efficacy against selected TBD
pathogens (i.e., A. platys, B. vogeli, and H. canis) in
young sheltered dogs living in an area where these infec-
tions are highly prevalent.Methods
Study design and study area
A parallel group-designed, randomised, controlled efficacy
field trial was conducted in a private shelter in the munici-
pality of Putignano (40°51′ N, 17°7′ E, 372 m above sea
level), province of Bari, Apulia region (southern Italy). The
ectoparasite fauna and TBDs occurring in dogs in this
shelter had been monitored over the previous three years
[1,10,22].The design and experimental procedures used in this
study were authorized by the Italian Ministry of Health
(DGSA n° 0001997; 04/02/2011). Moreover, this study was
conducted in accordance with the principles of Good
Clinical Practice (VICH GL9 GCP, 2000) adopted by the
Committee for Medicinal Products for Veterinary Use
(CVMP) in the guidelines for the evaluation of the efficacy
of antiparasitic substances against tick and flea infestation
in dogs and cats (EMEA/CVMP/005/00, 2000).
Animal management and care
Dogs enrolled in this study were young dogs (≤6 months
old) of both sexes. Each dog received two doses of a
vaccine against canine parvovirus, adenovirus type 2,
distemper virus, Leptospira canicola and Leptospira
icterohaemorrhagiae (DuramuneW DAPPi + LC; Zoetis,
Italy). In addition, all dogs were dewormed with a combin-
ation of praziquantel, pyrantel pamoate and fenbantel
(Drontal plusW; Bayer AG, Germany) at enrolment, and
were examined every two months and treated whenever a
faecal sample from a given cage was found positive for in-
testinal parasite eggs.
Dogs were housed in wire mesh enclosures (approx.
10 × 20 m) and fed commercial feed once per day, with
water provided ad libitum. At each treatment time point
(see below), the clinical status of each dog was recorded
on individual forms. The application of other ectoparasi-
ticides was not allowed during the study period except
once (i.e., June 2011), when heavy tick infestation was
recorded in untreated dogs.
Enrolment and follow up assessments
Dogs (n = 176) were enrolled into the study between
March and May 2011. On day 0 each dog was
microchipped, photographed, clinically examined and
searched for ticks and fleas. All data, including sex, age,
weight, and coat length, were recorded in appropriate
individual files. Dogs were excluded from the study if
under 7 weeks of age, if skin lesions were observed at
the site of product application or if physical examination
revealed a pre-existing disease.
The 176 enrolled dogs were randomly assigned to
groups A (dogs collared at day 0) and B (untreated control
dogs), but 52 of them died during the first weeks following
enrolment due to parvoviral gastroenteritis (data not
shown). The remaining dogs, reaching the first follow-up
assessment (see below), consisted of 64 dogs in group A
and 58 in group B. The homogeneity of the two groups in
relation to sex, age, weight, and coat length was evaluated
using chi-square test and one-way ANOVA.
Blood and serum samples were collected from all dogs
included in the trial at the first (July 2011), second
(September 2011), third (November 2011) and fourth
(April 2012) follow-up assessments.
Dantas-Torres et al. Parasites & Vectors 2013, 6:245 Page 3 of 8
http://www.parasitesandvectors.com/content/6/1/245All dogs were enrolled in the trial regardless of the re-
sults of the initial testing for the selected pathogens (see
below). The inclusion of positive dogs in both groups was
aimed at facilitating the circulation of pathogens within
the dog population under examination, as well as at
assessing the efficacy of the ectoparasiticide treatment at
the subsequent follow-ups. At baseline (March-May 2011)
collars were applied to all dogs from group A, according
to the manufacturer’s instructions: dogs ≤8 kg received a
small collar and dogs >8 kg received a large collar.
The collars were constantly worn and were replaced
within two days in case of accidental losses. In addition, a
new (large) collar was applied to dogs whose body weight
increased to over 8 kg. Finally, all collars were replaced
8 months after application, as per manufacturer’s instruc-
tions. All occurrences (collar replacement, etc.) were
recorded on the dog’s individual file. At the end of the
study period (April 2012), all collars were removed from
group A dogs and in October 2012 a complete blood sam-
ple collection was performed to determine the incidence
of TBDs amongst dogs previously collared (group A) or
not collared (group B). The laboratory staff were blinded
to treatment allocation of individual dogs, whereas the
shelter staff were not blinded due to the visible collar.
Estimation of flea and tick load
Dogs were examined monthly for the presence of ticks
and fleas by thumb counting, with examination of the
following body regions: head, ears, breast-neck, thorax,
abdomen, fore and back limbs, inter-digital areas, axilla,
tail and inguinal area. The number and/or developmen-
tal stages of ticks and fleas detected in the above men-
tioned body sites were recorded on a separate form for
each dog. Adult ticks were counted, whereas, due to the
exceedingly large number of immature ticks, a visual es-
timate was made of the ticks located in the neck, thorax,
abdomen, inter-digital and periocular areas and ears.
Each site was considered as an independent unit of cal-
culation. The load of immature ticks was grouped into
the following four infestation classes:
 Low: <10 immature ticks;
 Medium: <10x < 50 immature ticks;
 High: <50x < 100 immature ticks;
 Very high: ≥100 immature ticks.
Each of the four infestation classes was then multiplied
by the number of body sites in which that parasitic load
was estimated. Representative tick and flea specimens
were identified based on morphology [23-25].
Sample collection and diagnostic tests
Blood samples were collected from the brachial or jugular
veins in tubes with and without ethylenediaminetetraaceticacid (EDTA) anticoagulant. Room temperature coagulated
blood was centrifuged at 1,678 g for 10 min prior to
collecting the separated serum. Both the EDTA whole
blood and serum samples were stored at –20°C until
tested (see below).
Antibodies against B. canis and E. FLUOBABESIA
canis were detected using commercial IFAT kits
(MegaScreen Fluobabesia, MegaCor GmbH, Austria,
and Canine Ehrlichiosis FA Substrate Slide, VMRD,
Pullmann, Washington, USA, respectively). Cytological
examination of whole blood and buffy coat smears was
performed, following staining with MGG Quick Stain (Bio
Optica, Milan, Italy), for the presence of intracellular inclu-
sions of the most common tick-borne pathogens of dogs.
For the detection of Ehrlichia and Anaplasma species,
total DNA was extracted from EDTA-blood samples
using MagAttract DNA Blood Mini M48 Kits and
BioRobot M48 Workstation (Qiagen, Valencia, CA,
USA). DNA samples were screened by amplification of a
fragment of the groEL gene and a fragment of the 16S
rRNA gene, which are conserved across all Ehrlichia and
Anaplasma species [26,27]. All positive samples were ei-
ther sequenced directly (Genewiz, Inc., Research Tri-
angle Park, NC) for speciation or subsequently tested by
PCR assays designed for the detection of specific genetic
markers for A. platys [28], A. phagocytophilum [29], and
E. canis [10]. Babesia spp. DNA was amplified by PCR
targeting a variable region of the 16S-like rRNA gene
[30] and H. canis DNA by a PCR targeting a fragment of
the 18S rRNA gene [31], as described previously. Finally,
Bartonella spp. was amplified by PCR targeting a frag-
ment of the RNA polymerase b subunit (rpoB gene) as
described elsewhere [32].
Statistical analysis
The minimum sample size (n = 49) was calculated using
the software WinEpi (http://www.winepi.net/uk/index.
htm), to estimate differences between proportions (i.e.,
incidence) from the two populations. The following as-
sumptions were considered: (I) expected incidence in
group A = 5%; (II) expected incidence in group B = 15%;
(III) power = 85%; (IV) level of confidence = 95%. To ac-
commodate potential losses during the study period,
~60 instead of 49 dogs were enrolled in each group.
The incidence of tick-borne pathogen infection was
determined by Incidence Density rates (IDRs) [10,33],
which was calculated as follows: IDRs = number of posi-
tive dogs/number of dog-months of follow-up (i.e., the
number of months between the previous and the follow-
ing assessment for each dog at risk of infection). Dogs
were defined as “positive” if positive at any of the cyto-
logical, serological or PCR tests performed. Differences
between IDRs in groups A and B were calculated using a
Yates-corrected chi squared test. Dogs tested only once
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not contribute to the calculation of incidence, whereas
those sampled at least twice contributed to the IDR cal-
culation during the number of months those dogs
remained in the study. The post-treatment incidence
was calculated considering the test results obtained in
October 2012 in dogs that were negative both at enrol-
ment and April 2012 prior to the removal of the collar.
The efficacy of the collar against tick-borne pathogens
was calculated as follows: Efficacy = [(% of positive dogs
in group B − % of positive dogs in group A)/% of posi-
tive dogs in group B] × 100. For the calculation of the
overall efficacy against tick-borne pathogens, H. canis
was excluded, as this protozoon is not transmitted by
tick bites. The efficacy of the collar against ticks (imma-
ture and adult stages) and fleas was calculated as follows:
Efficacy = (mean ectoparasites load on control dogs –
mean ectoparasites load on treated dogs)/(mean ectopara-
sites load in control dogs) × 100. Collars were deemed
effective against ectoparasites if the calculated efficacy, based
on arithmetic and geometric means, was at least 90% [34].
Results
Dogs from group A (n = 64) and group B (n = 58) were
homogeneous (p > 0.05) in terms of number and individ-
ual characteristics (i.e., sex, age, weight, and coat length).
At baseline, 25 (20.5%) out of 122 dogs were positive for
at least one tick-borne pathogen. Specifically, 17.2% of
the dogs were infected with A. platys (i.e., 22% vs. 12%
in groups A and B, respectively), 11.5% with H. canis
(i.e., 10.9% vs. 9.1%), 4.9% with Babesia spp. (4.7% vs.
5.2%) and 1.6% with Bartonella spp. (3.1 vs. 0%). The
pathogen prevalence at baseline between the two groups
was not significantly different.
Two dogs were infected with Bartonella vinsonii subsp.
berkhoffii genotype III and one dog each was infected with
Bartonella henselae and Bartonella rochalimae. Co-
infections by two or more pathogens were documented in
16 dogs (13.1%), with seven dogs infected by A. platys and
H. canis, two dogs with A. platys and B. vogeli and two
dogs with A. platys and B. vinsonii subsp. berkhoffii geno-
type III. In three dogs, co-infection by three pathogens
was diagnosed (data not shown). All dogs were negative
for A. phagocytophilum and E. canis and only two dogs
were PCR-positive for B. vinsonii subsp. berkhoffii geno-
type III and B. rochalimae in group B. Thus, the efficacy
of the collar against these pathogens could not be
calculated.
The IDRs for all tick-borne pathogens at all follow-up
assessments were significantly higher in group B than in
group A (Table 1), resulting in an overall efficacy of
91.6%. For individual pathogens the efficacies were as
follows: 100% for B. vogeli; 91.1% for A. platys; and
43.4% for H. canis. At the end of the trial (April 2012),110 dogs (61 from group A and 49 from group B)
remained untreated and the post-treatment incidence,
calculated in October 2012 (Table 2), indicates A. platys
as the most common pathogen (incidence of 67.4% and
31% in groups A and B, respectively), followed by H.
canis (9.6% and 47.8%), B. vogeli (5.1% and 34.8%), and
B. vinsonii subsp. berkhoffii genotype III (4.1% in group
B only). Co-infections were detected in 25 (20.5%) dogs,
with eight dogs infected by A. platys and H. canis, eight
with B. vogeli and H. canis, six with A. platys and B.
vogeli, and three with A. platys, B. vogeli and H.
canis.
The mean tick and flea load in both group A and B
were comparable at baseline (p > 0.05). Conversely, the
tick burden was significantly higher in control dogs (p <
0.01) throughout the study period, resulting in an overall
efficacy against tick attachment of 99.7%, ranging from
95.3 to 100% and from 98.2 to 100% against adult and
immature ticks, respectively (Table 3). Importantly, only
11 ticks were collected from group A dogs during the
whole study period, being nine alive (eight adults and 1
immature) and two dead adults. All ticks collected were
morphologically identified as R. sanguineus group. Simi-
larly, a 100% efficacy against fleas was calculated for
each of the four assessments in which flea infestations
were detected (Table 4). The mean flea loads in groups
A and B were statistically different (p < 0.01) only at the
end of the season (September and November 2011). All
fleas collected were morphologically identified as C. felis.
Discussion
This study investigated, for the first time under field
conditions, the efficacy of a collar containing 10%
imidacloprid and 4.5% flumethrin for the prevention of
tick-borne pathogen infections in southern Europe,
where a range of canine vector-borne diseases are en-
demic [2,8]. The pre-trial prevalence of tick-borne
pathogen infections (e.g., A. platys, H. canis, Babesia
spp., and B. vinsonii subsp. berkhoffii genotype III) in
dogs, just prior to the beginning of the study, is in agree-
ment with the results of previous investigations
conducted in the same study site (see, for instance, Refs.
[4,9]). Importantly, the role of sheltered dogs as reser-
voirs of certain pathogens for pet dogs and humans
should be taken into account. For example, E. canis and
A. platys are potential zoonotic pathogens [1,35]. These
data highlight the need for the development of long-
lasting and cost-effective strategies for the prevention
and control of canine vector-borne diseases [8]. In par-
ticular, the use of collars impregnated with acaricidal/
repellent compounds has recently provided promising
results, indicating that long-lasting protection of dogs
against the most common canine vector-borne diseases
can be achieved in most instances [5,18]. Furthermore,
Table 1 Incidence density rates (IDRs) of and efficacy (%) against Anaplasma platys, Babesia vogeli and Hepatozoon
canis infections in dogs from groups A and B
Pathogen Number of dogs in the cohort Number of new infections Dog-months of follow-up IDRs Efficacy
A B A B A B A B
Anaplasma platys
Baseline 64 58 - - - -
Follow-up 1 50 51 6 24 134.5 109.7 53.5 262.6
Follow-up 2 44 23 4 18 115.7 59.8 41.5 361.2
Follow-up 3 40 5 0 2 82.8 12.5 0 192.8
Follow-up 4 40 3 0 0 162.8 12.5 0 0
Total 10 44 495.8 194.4 24.2 271.6 91.1%
Babesia vogeli
Baseline 64 58 - - - - - -
Follow-up 1 64 55 0 18 177.3 121.0 0 178.5
Follow-up 2 63 35 0 1 165.7 91.7 0 13.1
Follow-up 3 63 33 0 2 129. 8 68.0 0 35.3
Follow-up 4 63 30 0 0 256.4 120.3 0 0.0
Total 0 21 729.2 401.0 0 62.9 100%
Hepatozoon canis
Baseline 64 58 - - - - - -
Follow-up 1 57 51 25 27 156.8 109.7 191.4 295.5
Follow-up 2 32 23 10 8 84.5 59.3 142.1 161.8
Follow-up 3 22 15 1 4 45.5 31.1 26.4 154.6
Follow-up 4 21 11 0 3 85.5 45.7 0.00 78.9
Total 36 42 372.2 245.7 116.1 205.1 43.4%
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(e.g., spot-on), including prolonged efficacy, steady
concentration of the active compounds over its lifetime,
and increased owner’s treatment compliance (reviewed
by [11]).
The efficacy of the imidacloprid/flumethrin collar
has been previously evaluated against ticks (i.e., R.
sanguineus, I. ricinus, I. scapularis, D. reticulatus and D.
variabilis), mites (i.e. Sarcoptes scabiei), and lice
(Trichodectes canis) under controlled conditions [11].
The results of this trial complement the outcomes of theTable 2 Incidence of canine vector-borne pathogen
infections in the former groups A (treated) and B
(untreated), six months after the end of the study
(October 2012)*
Pathogen Positive/Total (%) Total (%)
Former group A Former group B
Anaplasma platys 33/49 (67.3)* 10/30 (33.3)* 43/79 (54.4)
Babesia vogeli 3/59 (5.1) 5/34 (14.7) 8/93 (8.6)
Bartonella spp. 0/60 (0.0) 2/48 (4.2) 2/109 (1.8)
Hepatozoon canis 5/52 (9.6)* 11/23 (47.8)* 16/75 (21.3)
*Statistically significant differences (p < 0.01) between former groups A and B.previous studies and further confirm the efficacy of this
collar as a prophylactic tool against the transmission of
tick-borne pathogens. Indeed, the high overall efficacy
(99.7%) against both adult and immature stages of ticks
resulted in a high level of protection against B. vogeli
and A. platys. The protection of dogs against ticks and
their transmitted pathogens is important, particularly be-
cause these pathogens have the potential to lead to se-
vere disease, especially in cases of co-infections [7,10].
Based on the results of the present study, the collar con-
ferred 100% protection against B. vogeli, 91.1% against
A. platys and 43.4% against H. canis. The observed dif-
ferences in levels of protection against distinct patho-
gens are likely related to a range of factors inherent to
the biology, ecology and transmission dynamics of such
pathogens [1,10]. For instance, the low efficacy of the
collar against H. canis infection registered in the present
study was expected considering that this protozoan is
not transmitted by tick bites, but orally when a dog in-
gests an infected tick [10,36]. Probably, H. canis infec-
tions detected in dogs from collared and control groups
were associated with an increase in the number of H.
canis-infected ticks in the environment during summer
months, as previously documented [1,37]. While the




Groups Mean 2011 2012
Day 0 May *Jun 1 *Jun 2 Jul Aug Sep Oct Nov Jan Feb Mar Apr
Adult A Arithmetic 37.5 0.2 0.2 0.1 0 0.1 0 0 0 0 0 0 0
Geometric 19.3 0.1 0.1 0.1 0 0.1 0 0 0 0 0 0 0
B Arithmetic 56.9 49.9 51.3 3.1 2.8 4.7 1.7 0.2 0.3 0.1 0.2 1.3 13.1
Geometric 22.8 19.8 39.8 2.0 1.1 3.0 1.1 0.1 0.2 0.1 0.1 0.8 10.0
Efficacy Ar. mean (%) - 99.6 99.6 96.7 100 97.9 100 100 100 100 100 100 100
Efficacy Ge. mean (%) - 99.5 99.8 95.0 100 96.7 100 100 100 100 100 100 100
Immature A Arithmetic 0.1 0 0 0 0 0 0 0 0 0 0 0 0
Geometric 0.1 0 0 0 0 0 0 0 0 0 0 0 0
B Arithmetic 0.1 1.8 4.3 106.3 0 0 0.3 0.1 0 0 0 0 4.5
Geometric 0.1 0.8 2.8 25.7 0 0 0.2 0.1 0 0 0 0 2.6
Efficacy Ar. mean (%) - 100 100 100 n.a. n.a. 100 100 n.a n.a n.a n.a 100
Efficacy Ge. mean (%) - 100 100 100 n.a n.a 100 100 n.a n.a n.a n.a 100
*Sampling occurred in monthly intervals. As it was conducted at beginning and end of June, June appears twice.
Abbreviations: n.a. not applied, Ar. arithmetic, Ge. geometric.
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pacts on the likelihood of a dog ingesting a H. canis-
infected tick, our findings suggest that integrated control
strategies focused on dogs and the environment may be
warranted. For instance, the level of tick infestation in
the environment might be particularly high in dog shel-
ters; therefore, the application of insecticides in the en-
vironment may be necessary to control high tick
burdens in this particular situation.
Molecular evidence of A. platys infection has been
reported in a range of tick species [38-40], even if the
role of ticks as vectors of this bacterium has yet to be
confirmed [41]. Remarkably, the very small number of
A. platys infections in dogs from group A demonstrates
the efficacy of the imidacloprid/flumethrin collar against
this pathogen and, indirectly, reinforces the hypothesis
that R. sanguineus group ticks may transmit A. platys
to dogs, especially considering the high incidence of
infection during the post-treatment phase recorded
herein.Table 4 Mean counts of Ctenocephalides felis and the efficacy
Group Mean 2011
Day 0 May *Jun 1 *Jun 2 Ju
A Arithmetic 0.7 0 0 0 0
Geometric 0.2 0 0 0 0
B Arithmetic 1.3 0 0 0 0
Geometric 0.5 0 0 0 0
Efficacy Ar. mean (%) - n.a. n.a. n.a. n.a
Efficacy Ge. mean (%) - n.a. n.a. n.a. n.a
*Sampling occurred in monthly intervals. As it was conducted at beginning and end
Abbreviations: n.a. not applied, Ar. arithmetic, Ge. geometric.Certainly, the efficacy of the collar against R.
sanguineus group ticks may potentially help in
preventing infection with pathogens other than B. vogeli
and A. platys, such as E. canis, as demonstrated under
laboratory conditions [19]. In fact, the overall efficacy
against both adult and immature ticks recorded in this
study is relevant, considering that most pathogens
harboured by R. sanguineus group ticks are passed
transstadially (e.g., H. canis and E. canis), while only a
few are transmitted transovarially (e.g., B. vogeli and R.
conorii) [42-44].
Conclusions
The long-term protection conferred by the imidacloprid/
flumethrin collar against fleas, ticks and tick-borne path-
ogens is in agreement with previous studies, in which
the efficacy of the collar was ascertained for up to
8 months [11]. However, it should be noted that, upon
removal of the collars, the prevalence of tick-borne in-
fections in dogs from group A increased dramaticallyduring the treatment period
2012
l Aug Sep Oct Nov Jan Feb Mar Apr
0 0 0 0 0 0 0 0
0 0 0 0 0 0 0 0
0.1 0.2 0 0.4 0 0 0 0.2
0.1 0.1 0 0.2 0 0 0 0.1
. 100 100 n.a. 100 n.a. n.a. n.a. 100
. 100 100 n.a 100 n.a n.a. n.a 100
of June, June appears twice.
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with previous observations [10] and advocates the need
for continued control of dogs against tick infestation, so
as to prevent tick-borne pathogen transmission. Indeed,
the availability of safe and effective acaricidal and/or
repellent products will undoubtedly assist in the estab-
lishment of long-term control programs to prevent
transmission of vector-borne diseases to dogs and may
also help to reduce potential risks for human health.
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